This review integrates mechanistic insights with translational advances, outlining how dysregulation of chaperones, autophagy-mitophagy, the ubiquitinproteasome system, and ER stress pathways drive human diseases, while highlighting emerging therapeutic platforms, from pharmacological chaperones and autophagy modulators to targeted protein degradation technologies, CRISPR screens, spatial biology, and AI-guided drug discovery
The relative infant dose (RID), or the maternal weight-adjusted infant dose, was calculated, considering the bioavailability of semaglutide and long-acting dose profiles
consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim and Novo Nordis k
Participants received once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 40 weeks
This content does not constitute medical advice, diagnosis, or treatment recommendations
Unpredictable Bowel Motility: The precise 8:3 ratio of soluble to insoluble fiber acts as a dual-action regulator, absorbing excess water to slow down rapid transit (diarrhea) while providing gentle, non-irritating bulk to assist a sluggish digestive tract (gastroparesis and constipation)
